Your browser doesn't support javascript.
loading
AA Amyloidosis: A Contemporary View.
Mirioglu, Safak; Uludag, Omer; Hurdogan, Ozge; Kumru, Gizem; Berke, Ilay; Doumas, Stavros A; Frangou, Eleni; Gul, Ahmet.
Afiliação
  • Mirioglu S; Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. smirioglu@gmail.com.
  • Uludag O; Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. smirioglu@gmail.com.
  • Hurdogan O; Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Kumru G; Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Berke I; Division of Nephrology, Ankara University Faculty of Medicine, Ankara, Turkey.
  • Doumas SA; Division of Nephrology, Marmara University School of Medicine, Istanbul, Turkey.
  • Frangou E; Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Gul A; Department of Nephrology, Limassol General Hospital, State Health Services Organization, Limassol, Cyprus.
Curr Rheumatol Rep ; 26(7): 248-259, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38568326
ABSTRACT
PURPOSE OF REVIEW Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis. RECENT

FINDINGS:

The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement. There is yet no treatment option for the clearance of amyloid fibril deposits; therefore, the management strategy primarily aims to reduce serum amyloid A protein. Anti-inflammatory biologic agents have drastically expanded our therapeutic armamentarium. Kidney transplantation is preferred in patients with kidney failure, and the recurrence of amyloidosis in the allograft has become rare as transplant recipients have started to benefit from the new agents. The management of AA amyloidosis has been considerably changed over the recent years due to the novel therapeutic options aiming to control inflammatory activity. New agents capable of clearing amyloid deposits from the tissues are still needed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Amiloidose Limite: Humans Idioma: En Revista: Curr Rheumatol Rep Assunto da revista: REUMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Turquia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Amiloidose Limite: Humans Idioma: En Revista: Curr Rheumatol Rep Assunto da revista: REUMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Turquia